Amy Gelfand, AHS 2021: COVID-19 Vaccines and Their Impact on Migraine Treatment
Access all of the content
touchNEUROLOGY had the pleasure of meeting with Amy Gelfand (University of California, San Francisco, CA, USA) to discuss what is known about the impact of preventative migraine medication on the COVID-19 vaccine.
The session ‘Vaccines and Their Impact on Migraine Treatment’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
Questions:
- What is the influence of NSAIDs on the immune response to vaccination? (0:17)
- Does acute migraine treatment impair the efficacy, or impact the safety, of the COVID-19 vaccine? (1:08)
- What is known about the impact of preventative migraine medication on the COVID-19 vaccine? (1:36)
- Does the COVID-19 vaccine adversely impact the efficacy of migraine treatments? (2:49)
- Should migraine patients be concerned about the risk of thrombosis after adenovirus COVID-19 vaccines? (3:20)
Disclosures: Amy Gelfand has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021.
